ARTICLE | Company News
GenVec, Novartis deal
January 25, 2010 8:00 AM UTC
GenVec granted Novartis exclusive, worldwide rights to GenVec's preclinical hearing loss and balance disorders program. The program uses GenVec's adenovector technology to deliver atonal homolog 1 ( ...